奥西默替尼
医学
间质性肺病
肺癌
表皮生长因子受体
腺癌
不利影响
肺
肿瘤科
内科学
酪氨酸激酶抑制剂
表皮生长因子
癌症
受体
埃罗替尼
作者
Wenyan Chen,Lijuan Zhang,Hui Shen,Bin Wang,Jiayou Luo,Enhai Cui
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2022-11-14
卷期号:34 (3): 460-466
被引量:1
标识
DOI:10.1097/cad.0000000000001436
摘要
Osimertinib, the third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for nonsmall cell lung cancer with EGFR mutation. However, osimertinib-induced interstitial lung disease (OsiILD) is considered to be a serious adverse event, so some patients will have to discontinue the use of osimertinib due to OsiILD. Almonertinib is a novel third-generation EGFR-TKI. We herein report a patient who developed OsiILD after the use of osimertinib and then switched to almonertinib for further treatment with success. This is the first report of a successfull rechallenge with low-dose almonertinib after OsiILD. We also reviewed the literature to explore the possible risk factors and the subsequent treatment of OsiILD, suggesting that low-dose almonertinib may be an option for follow-up treatment of OsiILD.
科研通智能强力驱动
Strongly Powered by AbleSci AI